{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'BIOCRYST', 'PHARMACEUTICALS, INC.', 'Protocol No. BCX7353-302', 'A PHASE 3, RANDOMIZED, DOUBLE-BLIND,', 'PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO', 'EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE', 'LEVELS OF BCX7353 AS AN ORAL TREATMENT FOR THE', 'PREVENTION OF ATTACKS IN SUBJECTS WITH', 'HEREDITARY ANGIOEDEMA', 'Version 4.0 (United States): 10 February 2020', 'IND No. 135,058', 'EudraCT No. 2017-003966-29', 'BioCryst Pharmaceuticals, Inc.', '4505 Emperor Blvd., Suite 200', 'Durham, NC 27703', 'Phone: (919) 859-1302', 'Fax: (919) 851-1416', 'CONFIDENTIAL', 'The information in this document contains proprietary and confidential information belonging to', 'BioCryst Pharmaceuticals, Inc. As a result, no part of this document should be copied, referred', 'to, released, published or otherwise disclosed in any manner or media without prior written', 'approval from BioCryst Pharmaceuticals, Inc.', '1']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', 'Protocol Number:', 'BCX7353-302', 'Study Title:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel group study to', 'evaluate the efficacy and safety of two dose levels of BCX7353 as an oral', 'treatment for the prevention of attacks in subjects with hereditary angioedema', 'IND Number:', '135,058', 'EudraCT No.', '2017-003966-29', 'Investigational Product:', 'BCX7353', 'Indication Studied:', 'Hereditary angioedema', 'Sponsor:', 'BioCryst Pharmaceuticals, Inc.', '4505 Emperor Boulevard, Suite 200', 'Durham, NC 27703, USA', 'Sponsor Medical Monitor:', 'Sylvia Dobo, MD', 'Phone (24 hours): +1 1 919-859-7905', 'Email: mm@biocryst.com', 'Clinical Study Manager:', 'Deb Kargl', 'Clinical Study Manager', 'BioCryst Pharmaceuticals', 'Office: + 1 919-797-2509', 'Email: dkargl@biocryst.com', 'Principal Investigator:', 'Bruce Zuraw, MD', 'Professor of Medicine', 'US HAEA Endowed Chair', 'Chief, Division of Rheumatology, Allergy & Immunology', 'Director, US HAEA Angioedema Center', 'UC San Diego', '+1 858-822-6597', 'bzuraw@ucsd.edu', 'Compliance Statement:', 'This study will be conducted in accordance with the ethical principles that have', 'their origin in the Declaration of Helsinki and clinical research guidelines', 'established by the Code of Federal Regulations (Title 21, CFR Parts 50, 56, and', '312), International Council for Harmonisation guidelines and all locally applicable', 'regulations. Essential study documents are currently archived in accordance with', 'applicable regulations', 'Final Protocol Date:', 'Version 4.0 (United States): 10 February 2020 (United States)', 'Previous Version(s):', 'Version 3.0: 11 September 2019', 'Version 2.0: 11 October 2018', 'Version 1.0: 21 November 2017', '2']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '1.1.', 'Protocol Approval Signature Page', 'Protocol No:', 'BCX7353-302', 'Protocol Title:', 'A Phase 3, randomized, double-blind, placebo-controlled, parallel group study', 'to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral', 'treatment for the prevention of attacks in subjects with hereditary angioedema', 'Date:', 'Version 4.0 (United States): 10 February 2020', 'BioCryst Pharmaceuticals, Inc.', 'Reviewed and Approved by:', 'Melane compent', '13 Feb 2020', 'Melanie Cornpropst, PharmD, PhD', 'Date', 'Vice President, Clinical Development', 'BioCryst Pharmaceuticals, Inc.', 'A', '13FOB 2020', 'Sylyia Dobo, MD', 'Date', 'Vide President, Medical and Safety Science', 'BioCryst Pharmaceuticals, Inc.', 'ilempany', '12 FEB 2020', 'Elliott Berger, PhD', 'Date', 'Senior Vice President, Regulatory Affairs', 'BioCryst Pharmaceuticals, Inc.', '3']\n\n###\n\n", "completion": "END"}